4D Pharma

7 articles with 4D Pharma

• 4D Pharma Announces Publication of Data Highlighting Immuno-Stimulatory Properties of MRx0518

  1/29/2019

  4D Pharma plc announces the publication of a paper outlining the mechanism and strong immuno-stimulatory effects of MRx0518.

• 4D pharma plc: Appointment of Independent Non-Executive Directors

  1/8/2019

  4D pharma plc today announces the appointment of Ed Baracchini, PhD, and Professor Axel Glasmacher, MD, as independent Non-Executive Directors with immediate effect.

• MD Anderson Cancer Center and 4D pharma collaborate to evaluate live biotherapeutics in solid tumors

  1/7/2019

  The University of Texas MD Anderson Cancer Center and 4D pharma today announced a strategic collaboration to evaluate 4D’s live biotherapeutic oncology pipeline across a range of cancer settings.

• 4D pharma and MD Anderson Cancer Center to Evaluate Live Biotherapeutics in Solid Tumours

  1/7/2019

  4D pharma plc and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to evaluate 4D's Live Biotherapeutic oncology pipeline across a range of cancer settings.

• 4D Presents at IHMC 2018

  6/27/2018

  Dr. Alex Stevenson, has spoken at the International Human Microbiome Consortium (IHMC) 2018 on the importance of function in the development of live biotherapeutics.

• 4D pharma plc Enters Into Clinical Collaboration Agreement With MSD Investigating the Combination of KEYTRUDA® (pembrolizumab) and MRx0518 in Patients With Solid Tumours

  6/7/2018

  4D pharma plc is a clinical stage biopharmaceutical company, pioneering the development of Live Biotherapeutic Products

• Manchester's 4D Pharma Reels In $29 Million

  6/26/2014